Список литературы

1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13): 1201 - 1214.

2. NMPN Study Group. Guidelines for the diagnosis and treatment of eosinophilia. 2nd version, September 2012, www.nordicmpd.org.:4.

3. Havelange V, Demoulin J-B. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with eosinophilia. Journal of Blood Medicine 2013; 4: 111 - 121.

4. Jawhar M, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic and blast phase. Annals of Hematology 2017; 96 (9): 1463 - 1470.

5. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood 2017; 129: 704 - 714.

6. Chase A, Bryant C, Score J, Cross NC. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; 98 (1): 103 - 106.

7. Reiter A, Walz C, Watmore A, et al. The t(8; 9) (p22; p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65 (7): 2662 - 2667.

8. Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 2014; 166 (6): 809 - 817.

9. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391 - 2324.

10. Gotlib J, Cools J, Malone JM, et al. The fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 2004; 103: 2879 - 2891.

11. Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the Unites States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126: 179 - 181.

12. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012; 5 (2): 157 - 176.

13. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 2014; 89: 325 - 337.

14. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347 (7): 481 - 487.

15. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103 (2): 473 - 478.

16. Muller AM, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1 - 16.

17. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92 (9): 1173 - 1179.

18. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion-gene positive and BCRABL-negative chronic myeloproliferative disorders. Blood 2007; 109: 61 - 64.

19. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109 (11): 4635 - 4640.

20. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124 (6): 1319 - 1325.

21. Klion AD. How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736 - 3741.

22. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85 (2): 158 - 164.

23. Helbig G, Moskwa A, Hus M, et al. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript - results of Polish multicentre study. Hematol Oncol 2010; 28 (2): 93 - 97.

24. Bochner BS, Gleich GJ. What targeting eosinophils has taught us about their role in disease. J Allergy Clin Immunol 2010; 126: 16 - 25.

25. Pardanani A, D'Souza A, Knudson RA, et al. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia 2012; 26 (11): 2439 - 2441.

26. Helbig G, Hus M, Halasz M, et al. Imatinib mesylate may induce long-term clinical response in hypereosinophilic syndrome. Med Oncol 2012; 29: 1073 - 1076.

27. Legrand F, Renneville A, Macintyre E, et al; on behalf of the French Eosinophil Network. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine (Baltimore). 2013; 92 (5): e1 - e9.

28. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123 (23): 3574 - 3577.

29. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978; 89: 167 - 172.

30. Fauci AS, Harley JB, Roberts WC, et al. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97: 78 - 92.

31. Coutant G, , Prin L, Hauteville D, et al. Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases. Ann Med Interne (Paris) 1993; 144: 243 - 250.

32. Weller, P.F. & Bubley, G.J. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759 - 2779.

33. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alpha. J Allergy Clin Immunol 1994; 94: 1318 - 1326.

34. Ouiquandon I, Claisse JF, Capiod JC, et al. Alpha-interferon and hypereosinophilic syndrome with trisomy 8: Karyotypic remission. Blood 1995; 85: 2284 - 2285.

35. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92: 176 - 183.

36. Yamada O, Kitahara K, Imamura K, et al. Clinical and cytogenetic remission induced by in a patient with chronic eosinophilic leukemia associated with a unique t(3; 9; 5) translocation. Am J Hematol 1998; 58 (2): 137 - 141.

37. Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: Consideration of five cases. Ann Hematol 1998; 77: 161 - 164.

38. Luciano L, Catalano L, Sarrantonio C, et al. hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1; 5). Haematologica 1999; 84: 651 - 653.

39. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: Report of a case and literature review. J Dermatol 2000; 27: 110 - 115.

40. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114: 26 - 40.

41. Helbig G, Stella-Holowiecka B, Majewski M, et al. Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation. Haematologica 2007; 92 (11): e118 - e119.

42. Bjerrum OW. Interferon treatment in patients with hypereosinophilia. Curr Drug Target 2011, 12: 429 - 432.

43. Blacklock HA, Cleland JF, Tan P, Pillai VM. The hypereosinophilic syndrome and leukapheresis. Ann Intern Med 1979; 91: 650 - 651.

44. Davies J, Spry C. Plasma exchange or leukapheresis in the hypereosinophilic syndrome. Ann Intern Med 1982; 96: 791.

45. Chambers LA, Leonard SS, Whatmough AE, et al. Management of hypereosinophilic syndrome with chronic plasma- and leukapheresis. Prog Clin Biol Res 1990; 337: 83 - 85.

46. Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52: 1 - 22.

47. Narayan S, Ezughah F, Standen GR, et al. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol 1993; 148: 817 - 820.

48. Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med 1998; 91: 492 - 493.

49. Harley JB, McIntosh XL, Kirklin JJ, et al. Atrioventricular valve replacement in the idiopathic hypereosinophilic syndrome. Am J Med 1982; 73: 77 - 81.

50. Cameron J, Radford DJ, Howell J, et al. Hypereosinophilic heart disease. Med J Aust 1985; 143: 408 - 410.

51. Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 1988; 46: 570 - 571.

52. Chandra M, Pettigrew RI, Eley JW, et al. Cine-MRI-aided endomyocardectomy in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 1996; 62: 1856 - 1858.

53. Radford DJ, Garlick RB, Pohlner PG. Multiple valvar replacement for hypereosinophilic syndrome. Cardiol Young 2002; 12: 67 - 70.

54. Kiris I, Okutan H, Peker T, et al. Mitral valve replacement in a patient with idiopathic hypereosinophilic syndrome and pulmonary artery hypertension. J Card Surg 2009; 24: 80 - 82.

55. Juvonen E, Volin L, Kopenen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002; 29: 457 - 458.

56. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119: 131 - 134.

57. Vazquez L, Caballero D, Canizo CD, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant 2000; 25: 217 - 218.

58. Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: Long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006; 38: 319 - 320.

59. Медицинская реабилитация/Под ред. В.М. Боголюбова. - Изд. 3-е, испр. и доп. - М.: Издательство БИНОМ, 2010. 416 с.

60. Оксфордский центр доказательной медицины. Уровни доказательности (Май 2001). Разработали Боб Филипс К.Б., Дейв Сакетт, Доуг Баденох, Шарон Штраус, Брайен Хайнес, Мартин Давес в ноябре 1998.